Analysis of malignancy predictors for follicular thyroid tumors

Goran V. Zorić*, Marina M. Nikolić-Djurović†, Ivan R. Paunović*,
Aleksandar D. Dikli*, Zoran M. Bukumirić†, Nikola S. Sljepčević*†,
Katarina M. Tausanović*, Božidar A. Odalović*, Milan D. Jovanović*,
Vladan R. Živaljević*†

Clinical Centre of Serbia, *Centre for Endocrine Surgery, Clinical Centre of Serbia, †Faculty of Medicine, ‡Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade, Serbia; University of Belgrade, *Faculty of Medicine, †Institute for Medical Statistics and Informatics, Belgrade, Serbia

Abstract

Background/Aim. Establishing a preoperative diagnosis of thyroid follicular tumors is difficult due to the fact that the cell morphology of adenomas and carcinomas are similar and that capsular and vascular invasion cannot be determined by cytology. We analyzed predictive factors of follicular carcinoma in order to enable a surgeon to indicate operative treatment and to perform an adequate operation for each patient with a follicular neoplasm. Methods. In this retrospective study, we analyzed medical records of all patients with follicular thyroid tumors operated at an endocrine surgery unit of a tertiary referral academic hospital, between 2008 and 2012. A total of 263 operated patients were included and divided into follicular adenomas (n = 97) and follicular carcinomas (n = 166) based on the histopathology results. The most important demographic and clinical characteristics were analyzed by univariate and multivariate logistic regression analysis. Results. In adenoma group (19 males, 78 females) age range was 19–79, mean age 50. In carcinoma group (35 males, 131 females) age range was 15–78, mean age 48. Univariate analysis showed that thyroglobulin concentration ≥ 500 ng/mL, tumor diameter < 30 mm, presence of more than one thyroid nodule and an afunctional/hypofunctional nodule were significantly more frequent in follicular carcinoma than in follicular adenoma. Independent predictive factors of malignancy were: elevated preoperative thyroglobulin concentration (≥ 500 ng/mL) and presence of more than one nodule. Based on our results we formed a nomogram, a two-dimensional diagram designed to enable estimation of preoperative probability of malignancy. Conclusion. Elevated preoperative thyroglobulin concentration, ≥ 500 ng/mL, and the presence of more than one nodule are independent predictors of malignancy for follicular thyroid carcinomas.

Key words: thyroid neoplasms; diagnosis; diagnosis, differential; thyroidectomy; thyroglobulin; nomograms.

Apstrakt

Uvod/Cilj. Prema raspoloživim dijagnostičkim metodama nije moguće preoperativno razlikovati benigne od malignih folikulske tumora štitaste žlezde, a najčešće ni intraoperaativno zbog veoma slične čeljske morfološke strukture i neumogućnosti histološkog dokaza invazije kapstule ili krvnih sudova karakteristične za štitastu žlezdu. U ovaj proučavanja istraživali su se pouzdaniji preoperativni kriteriji maligniteta kod bolesnika s folikulskim karcinomom štitaste žlezde koji bi omogućili ispravnu selekciju bolesnika za operativno lečenje, a potom i izvođenje adekvatnog tipa operacije kod bolesnika s folikulskom tireoidnom neoplazom. Metode. Ovom retrospektivnom studijom su obuhvaćeni svi bolesnici operisani zbog postojanja folikulskog tumora štitaste žlezde u tercijarnoj univerzitet-
Introduction

Primary thyroid malignancies, according to their cell origin are divided into two groups: larger, from follicular cells (papillary, follicular, oxyphilic and anaplastic carcinoma – more than 90%) and smaller, which originate from C-cells (medullary carcinoma, less than 10%).

The aim of the modern medicine is to know the nature of the tumor preoperatively or at least intraoperatively. The best tests to predict malignancy and the need for surgery in patients with thyroid nodules are fine-needle aspiration biopsy (FNAB) and measurement of serum calcitonin for medullary cancer. The reported accuracy of FNAB ranges from 70–90%. It is useful in the diagnostics of goiter, some benign thyroid tumors (like colloid adenoma or cysts), papillary and anaplastic carcinoma; but it is not reliable in distinguishing benign from malignant follicular and Hurthle-cell neoplasms.

Follicular adenoma and follicular carcinoma give the same cytological diagnosis – follicular lesion that includes both, benign follicular tumors (adenomas) and malignant (follicular carcinomas and follicular variant of papillary cancer). The role of the intraoperative frozen-section examination is controversial for those two types of thyroid tumor, too.

Consequently, it is difficult to establish a correct preoperative diagnosis for follicular tumors because of a very similar benign and malignant cytological morphology and because of the fact that capsular and vascular invasion cannot be verified by cytological examination. Up to 70% of these patients with a diagnosis of follicular lesion undergo surgery for benign disease with risk of surgical complications. The need for a thyroidectomy completion increases the risk of complications and the costs.

Methods

In this retrospective study, we analyzed medical records of all patients with follicular tumors of the thyroid operated at an endocrine surgery unit of a tertiary referral academic hospital, in a five-year period (2008–2012). The study was approved by the Ethic Committee of the tertiary referral university hospital. A total of 263 patients were included and divided, on the basis of definite histopathology, into two groups: 1) follicular adenomas (97 patients) and 2) follicular carcinomas and follicular variant of papillary cancer (166 patients – 11 follicular carcinomas and 155 patients with follicular variant of papillary cancer). The most important demographic and clinical characteristics were analyzed (n = 34) including gender (male/female), age (≤ 50/> 50 years), smoking (smokers/nonsmokers), duration of disease (> 60/≤ 60 months), type of operation, tumor diameter (≤ 30/> 30 mm), type of nodule (dominant, non-dominant/solitary), multifocality of the tumor (yes/no), microcalcifications (yes/no), echostructure (iso-, hyper-, hypoechogenic/hypoechoic), vascularization of nodule (irregular/regulat), scintigraphy (functional and hypofunctional functional and hyperfunctional), thyroid functional status (hypothyroid, euthyroid, hyperthyroid), level of serum thyroglobulin (≥ 500 ng/mL), anti-thyroglobulin (Tg) antibodies (increased/normal), anti-thyroperoxidase (TPO) antibodies (increased/normal), coexisting benign thyroid diseases (yes/no), coexisting Hashimoto thyroiditis (yes/no), coexisting Graves’ disease (yes/no), coexisting multinodular goiter (yes/no), coexisting thyroid adenoma (yes/no), coexisting malign thyroid diseases (yes/no), coexisting oxyphilic carcinoma (yes/no), coexisting papillary carcinoma (yes/no), coexisting micropapillary carcinoma (yes/no), coexisting malignant tumors of other organs (yes/no), presence of arterial hypertension (yes/no), diabetes mellitus (yes/no), ABO, Rh, presence of benign (yes/no) and malignant (yes/no) family thyroid diseases and other malignant family diseases (yes/no). Dichotomy of continuing variables was made on the base of data distribution and referral literature value.

The Cox regression model was used in statistical data processing. All the variables were tested by univariate logistic regression analysis and those with a p < 0.05 were included in the multivariate logistic regression analysis to test for independence in the prediction of malignancy with a 95% confidence interval (CI) for the odds ratio (OR). A p value < 0.05 was considered as statistically significant. Based on our results we formed a nomogram, a two-dimensional diagram designed to enable calculation of preoperative probability of malignancy. The software package SPSS 12.0 for windows was used for all statistical analyses.

Results

Over the study period, there were 263 patients who underwent surgical treatment: 97 (36.9%) with benign histology of follicular adenoma and 166 (63.1%) with malignant
histology of follicular carcinoma (n = 11) or follicular variant of papillary carcinoma (n = 155). Results are presented in Tables 1 to 3.

### Table 1

**Demographic and clinical characteristics of all patients**

| Characteristics                  | Adenoma | Carcinoma |
|----------------------------------|---------|-----------|
| Gender                           |         |           |
| male                             | 19 (19.6) | 35 (21.1) |
| female                           | 78 (80.4) | 131 (78.9) |
| Age (years)                      |         |           |
| ≤ 30                             | 12 (12.4) | 21 (12.7) |
| 31–40                            | 15 (15.5) | 37 (22.3) |
| 41–50                            | 18 (18.6) | 36 (21.7) |
| 51–60                            | 26 (26.8) | 41 (24.7) |
| 61–70                            | 21 (21.6) | 20 (12.0) |
| ≥ 71                             | 5 (5.2)  | 11 (6.6)  |
| Smoking                          |         |           |
| smokers                          | 24 (32.4) | 45 (36.6) |
| former smokers                   | 15 (20.3) | 18 (14.6) |
| nonsmokers                       | 35 (47.3) | 60 (48.8) |
| Disease duration (months)        |         |           |
| ≤ 11.9                           | 13 (13.8) | 35 (22.3) |
| 12–35.9                          | 19 (20.2) | 27 (17.2) |
| 36–59.9                          | 15 (16.0) | 27 (17.2) |
| 60–119.9                         | 21 (22.3) | 26 (16.6) |
| 120–239.9                        | 16 (17.0) | 28 (17.8) |
| Thyroid functional status        |         |           |
| hypothyroidism                   | 4 (4.1)  | 8 (4.8)   |
| euthyroidism                     | 85 (87.6) | 147 (89.1) |
| hyperthyroidism                  | 8 (8.2)  | 10 (6.1)  |
| Thyroglobulin (ng/mL)            |         |           |
| ≥ 500                            | 3 (5.4)  | 19 (17.1) |
| < 500                            | 53 (94.6) | 92 (82.9) |
| Anti-Tg antibodies               |         |           |
| increased                        | 8 (18.6) | 22 (21.4) |
| normal                           | 35 (81.4) | 78 (78.6) |
| Anti-TPO antibodies              |         |           |
| increased                        | 10 (24.4) | 23 (26.4) |
| normal                           | 31 (75.6) | 64 (73.6) |
| Type of operation                |         |           |
| hemithyroidectomy                | 44 (45.4) | 46 (27.7) |
| lobectomy with partial resection | 0 (0.0)  | 5 (3.0)   |
| near-total thyroidectomy         | 5 (5.2)  | 11 (6.6)  |
| thyroidectomy with/without dissection | 48 (49.5) | 104 (62.7) |

**Anti-TPO antibodies** – antithyroperoxidase antibodies; **Anti-Tg antibodies** – anti-thyroglobulin antibodies.

In the adenoma group (19 males, 78 females) age ranged from 19 to 79 with a mean age of 50 years. In the carcinoma group (35 males, 131 females) age ranged from 15–78 with a mean age of 48 years. The mean tumor diameter in the adenoma group was 37.5 mm (median 36, range 12–150 mm) and 33.4 mm (median 30, range 3–90 mm) in the carcinoma group. The mean preoperative level of thyroglobulin in the adenoma group was 226.6 ng/mL, and 320.3 ng/mL in the carcinoma group.

Patients in the carcinoma group significantly more often had more than one nodule ($p = 0.012$) below 30 mm in diameter ($p = 0.021$), afunctional on scintigraphy ($p < 0.01$), serum thyroglobulin level $\geq 500$ ng/mL ($p = 0.045$) and coexisting thyroid adenomas ($p < 0.01$).

Coexisting malignant thyroid diseases ($p < 0.01$), thyroid micropapillary ($p = 0.027$) and papillary carcinomas ($p < 0.01$) were significantly more frequent in the group of adenomas.

There were no significant differences between these two groups regarding gender, age, smoking, disease duration, consistence of nodule, microcalcifications, echostructure, nodule vascularization, thyroid functional status, levels of anti-Tg and anti-TPO antibodies, coexisting benign thyroid diseases (Hashimoto thyroiditis, Graves’ disease, nodular and multinodular goiter), coexisting oxyphilic carcinoma and malignant tumors of other organs, arterial hypertension, diabetes mellitus, ABO, Rh, benign and malignant family thyroid diseases and other malignant diseases in family.

All variables that can be preoperatively determined were included in the univariate regression analysis. Results are presented in Table 4.

Univariate analysis showed that thyroglobulin concentration greater or equal than 500 ng/mL, tumor diameter $< 30$ mm, presence of more than one thyroid nodule and an afunctional/hypofunctional nodule on scintigraphy were significantly more frequent in patients with follicular carcinoma compared to patients with follicular adenoma.

---

Zorić G, et al. Vojnosanit Pregl 2020; 77(3): 282–288.
All variables with a \( p \) value < 0.05 were included in the multivariate logistic regression model (Table 5). Independent predictive factors were elevated preoperative thyroglobulin concentration, \( \geq 500 \text{ng/mL} \), and a presence of more than one nodule. Scintigraphy findings were excluded from analysis because of a small number of patients with them. The whole model with all predictors was statistically significant \( (p < 0.001) \). There was no significant multi-collinearity among the predictors.

According to multivariate regression analysis, statistically significant predictors for follicular thyroid cancer were: type of nodule (dominant and non-dominant/solitary) \((OR = 2.71, 95\% \text{CI 1.36–5.38})\), which means that patients with more than one nodule have almost three times a bigger chance to have follicular cancer in relation to patients with a solitary nodule; preoperative serum thyroglobulin concentration \( \geq 500 \text{ng/mL} \) with \( OR = 4.18, 95\% \text{CI 1.14–15.33} \). Patients with Tg \( \geq 500 \text{ng/mL} \) had over four times a bigger chance for follicular cancer.

Based on our results we formed a nomogram, a two-dimensional diagram designed to enable calculation of preoperative probability of malignancy (Figure 1). It may help to improve clinical management of patients with follicular lesions.

### Discussion

The incidence of malignancy in patients with thyroid follicular tumors lies between 12% and 30% 4–7. In our study it was 63.1%. The research of Paramo and Mesko 8 (71 patients with follicular neoplasm) showed that the incidence of malignancy was 13% in men and 13% in women. In the study of Petric et al. 9, the malignancy rate was 43% in males and 23% in female patients with follicular and Hurthle cell neoplasms with a diameter of 2 cm or less.

The frozen section findings and FNAB are not a reliable method for distinguishing between benign and malignant follicular nodules. The discrimination between follicular adenoma and carcinoma can only be made postoperatively. Possible predictive factors of follicular carcinoma can help a surgeon to indicate operative treatment and to perform an adequate operation for each patient with a follicular thyroid neoplasm.

In the present study, univariate analysis showed that a tumor diameter < 30 mm was significantly more frequent in patients with follicular carcinoma.
Table 4

| Independent variable                                      | $p$   | OR   | 95% CI |
|-----------------------------------------------------------|-------|------|--------|
| Gender (male/female)                                      | 0.772 | 0.91 | 0.49 1.70 |
| Age                                                       | 0.195 | 0.98 | 0.97 1.01 |
| Age (50 years)                                            | 0.109 | 0.66 | 0.40 1.10 |
| Smoking (smokers/nonsmokers)                             | 0.840 | 0.94 | 0.53 1.68 |
| Disease duration (> 60/≤ 60 months)                      | 0.399 | 0.80 | 0.48 1.34 |
| Tumor diameter (< 30 mm/≥ 30 mm)                         | 0.022 | 1.81 | 1.09 3.00 |
| Type of nodule (dominant and non-dominant/solitary)      | 0.022 | 1.81 | 1.09 3.00 |
| Microcalcifications (yes/no)                             | 0.265 | 1.49 | 0.74 3.02 |
| Echostucture (iso, hyper, heteroechoic/hypoechoic)       | 0.360 | 0.73 | 0.38 1.42 |
| Nodule vascularization (irregular/regular)               | 0.222 | 1.80 | 0.70 4.62 |
| Scintigraphy (afunctional and hypofunctional)            | 0.005 | 5.47 | 1.68 17.81 |
| Thyroid functional status                                | 0.501 | 0.77 | 0.37 1.63 |
| Serum Tg                                                  | 0.157 | 1.00 | 1.00 1.00 |
| Serum Tg (≥ 78 ng/mL/≤ 78 ng/mL)                         | 0.672 | 1.16 | 0.59 2.28 |
| Serum Tg (≥ 500 ng/mL/≤ 500 ng/mL)                       | 0.045 | 3.65 | 1.03 12.91 |
| Anti-TPOAb (positive/negative)                           | 0.805 | 1.11 | 0.47 2.63 |
| Coexisting Hashimoto thyroiditis. (yes, no)              | 0.190 | 0.62 | 0.30 1.27 |
| Coexisting goiter (yes, no)                              | 0.109 | 0.65 | 0.38 1.10 |
| Coexisting Graves’ disease (yes, no)                     | 0.999 | -    | -     |
| Arterial hypertension (yes, no)                          | 0.294 | 0.76 | 0.46 1.27 |
| Diabetes mellitus (yes, no)                              | 0.191 | 2.14 | 0.68 6.70 |

OR – odds ratio; CI – confidence interval; Tg – thyreoglobulin; Anti TPOAb – antithyreoperoxidase antibodies.
Note: statistically significant values are bolded.

Table 5

| Independent variable                                      | $p$   | OR   | 95% CI |
|-----------------------------------------------------------|-------|------|--------|
| Tumor diameter (< 30 mm/≥ 30 mm)                         | 0.063 | 1.92 | 0.96 3.83 |
| Type of nodule (dominant and non-dominant/solitary)      | 0.004 | 2.71 | 1.36 5.38 |
| Thyroglobulin (≥ 500 ng/mL/≤ 500 ng/mL)                  | 0.031 | 4.18 | 1.14 15.33 |

OR – odds ratio; CI – confidence interval.

Fig. 1 – Nomogram-preoperative probability of malignancy for follicular thyroid tumors.
The diameter of follicular tumors as a predictive factor for carcinoma has been mentioned in literature many times 1, 9, 12, 13. In the study of 616 patients with follicular adenoma, follicular carcinoma and follicular variant of papillary cancer, nodules ≥ 4 cm were associated with increased odds of a benign lesion which is in correlation to our research. In the same study, a family history of thyroid cancer was associated with increased odds of malignancy which was not proven in our study 10. Petric and Mesko 4 reported that a tumor > 4 cm is a predictive parameter of malignancy in follicular neoplasms. Gulcelik et al. 3 in their study of 98 patients with follicular neoplasm did not find a statistical significance, although the mean nodule size was slightly larger in malignant nodules. Risk of malignancy was higher in nodules measuring 2 cm or larger according to the results of Reparia et al. 12. In the study of Petric et al. 9 the tumor diameter did not correlate with the malignancy rate. Tumor volume was found to be an independent predictor for follicular thyroid cancer (FTC) in all patients with a cytological diagnosis of follicular lesion 14.

Adenomas are usually solitary, less than 3 cm, but a significant numbers of exceptions exist 15. In our study, univariate analysis showed that the presence of more than one thyroid nodule was significantly more frequent in patients with follicular carcinoma and it was an independent predictive factor in the multivariate logistic regression model. Gulcelik et al. 3 published similar results, in their study the presence of a solitary nodule was not predictive for malignancy. Unlike this, Najafian et al. 16 came out with data that multinodularity on physical examination was associated with an increased odds of a benign lesion.

Deviation of our results regarding incidence of malignancy, tumor size and type of nodule may be caused by a minority of follicular carcinomas in regard to the number of follicular variant of papillary carcinomas in the carcinoma group.

Serum thyroglobulin is primarily used in the postoperative cancer monitoring for differentiated thyroid carcinomas, but it could indicate differentiated cancer with controversial usefulness. In our study, the mean preoperative thyroglobulin level in the adenoma group was 226.6 ng/mL and 320.3 ng/mL in the carcinoma group. Thyroglobulin level over 500 ng/mL, and the presence of more than one thyroid nodule are independent predictors of malignancy for follicular thyroid cancers. The nomogram presented in this study could help to improve the clinical management of patients with follicular thyroid lesions.

REFERENCES

1. Ito Y, Miyachi A. Prognostic Factors and Therapeutic Strategies for Differentiated Carcinomas of the Thyroid. Endocr J 2009; 56: 177–92.
2. Gulcelik NE, Gulcelik MA, Kurn B. Risk of Malignancy in Patients With Follicular Neoplasm. Arch Otolaryngol Head Neck Surg 2008; 134(12): 1312–5.
3. Hamburger JI, Haasen M. Contribution of intraoperative pathology evaluation to surgical management of thyroid nodules. Endocrinol Metab Clin North Am 1998; 19(3): 509–22.
4. Sahin M, Garson A, Tutuncu NB, Gaviour DN. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clin Endocrinol (Oxford) 2006; 65(4): 5148.
5. Miller B, Burkey S, Lindberg G, Snyder WTJ, Nawariakn FE. Prevalence of malignancy with cytologically indeterminate thyroid nodules. Am J Surg 2004; 188(5): 459–62.
6. Goldstein RE, Neiterrille JL, Burkey B, Johnson JE. Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. Ann Surg 2002; 235(5): 656–62.
7. Raber W, Kaserer K, Niederle B, Vierbapper H. Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. Thyroid 2000; 10(8): 709–12.
8. Paramo JC, Mosko T. Age, tumor size, and in-office ultrasonography are predictive parameters of malignancy in follicular neoplasms of the thyroid. Endocr Pract 2008; 14(4): 447–51.
9. Petric R, Besic H, Besic N. Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hurthle cell neoplasms of the thyroid gland. World J Surg Oncol 2014; 12: 282.
10. Calò PG, Modai F, Santa Cruz R, Puddu F, Ercoli E, Pisano G, Nicolai A. Follicular nodules (Thy3) of the thyroid: is total thyroidectomy the best option? BMC Surg 2014; 14: 12.
11. Zdon MJ, Fredland AJ, Zaret PH. Follicular neoplasms of the thyroid. Predictors of malignancy? Am Surg 2001; 67(9): 880–4.
12. Regara K, Miu SK, Moody DR, Austin R, Amikchaki M. Clinical outcomes for “suspicious” category in thyroid fine-needle biopsy: Patient’s sex and nodule size are possible predictors of malignancy. Arch Pathol Lab Med 2009; 133(5): 787–90.
13. Gulesnik NE, Gulesnik MA, Kurn B. Risk of Malignancy in Patients With Follicular Neoplasm. Arch Otolaryngol Head Neck Surg 2008; 134(12): 1312–5.
14. Kim HJ, Mok JO, Kim CH, Kim YJ, Kim SJ, Park HK, et al. Preoperative serum thyroglobulin and changes in serum thyroglobulin during TSH suppression independently predict follicular thyroid carcinoma in thyroid nodules with a cytohistological diagnosis of follicular lesion. Endocr Res 2017; 42(2): 154–62.
15. Davis NL, Gordon M, Germann E, Robini RE, McGregor GI. Clinical parameters predictive of malignancy of thyroid follicular neoplasms. Am J Surg 1991; 161(5): 567–9.
16. Najafian A, Olsen MT, Schneider EB, Zeiger MA. Clinical presentation of patients with a thyroid follicular neoplasm: are there preoperative predictors of malignancy? Ann Surg Oncol 2015; 22(9): 3007–13.
17. Besic N, Sukek M, Peric B, Zgajnar J, Hocevar M. Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit 2008; 14(9): CR459–67.
18. Hyvärtilansuo J, Tulinius H, Kjeld M, Siguldaan H, Jónason JG. Serum thyroglobulin as a risk factor for thyroid carcinoma. Acta Oncol 2000; 39(8): 973–7.
19. Panza N, Lambardi G, De Rosa M, Paolino G, Laterza L, Salvatore M. High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer 1987; 60(9): 2233–6.
20. Sub I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg 2010; 200(1): 41–6.
21. Kaiko E, Nagachi S, Yamashita H, Morishami T, Ohashima A, Kanamoto H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001; 136(3): 334–7.
22. Leenhart H, Higashih M, Franck B, Fudaiansky LD, Dillot T, Le Guillouzie D, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84(1): 24–8.
23. Jovanovic MD, Zipalovic VR, Dikic AD, Rasovic BR, V Zoric G, Panovic IR. Surgical treatment of concomitant thyroid and parathyroid disorders: analysis of 4882 cases. Eur Arch Otorhinolaryngol 2017; 274(2): 997–1004.

Received on March 14, 2018.
Revised on April 13, 2018.
Accepted on April 16, 2018.
Online First April, 2018.